We focused on four particular time series datasets: human aortic smooth muscle cells (AoSMC) treated with FGF2 and with IL-1β (9 time points from 0 to 360 min; 3 replicates per treatment; IL-1β will be referred to as IL1b hereafter), as well as human MCF7 breast cancer cells treated with EGF and HRG (16 time points from 0 to 480 min; 3 replicates per treatment). This evidence concerns the gene FGF2 and breast cancer.